ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), today announced the appointment of Kevin Yen as Vice President of Administration. He will report directly to Dr. Jo Shen, President and CEO of ScinoPharm.

ScinoPharm Taiwan, Ltd. (TWSE: 1789) specializing in the development and manufacture of active pharmaceutical ingredients, and TaiGen Biotechnology (4157.TW; F*TaiGen) jointly announced today the signing of a manufacturing contract for the clinical supply of the API of Burixafor, a new chemical entity discovered and developed by TaiGen.

ScinoPharm Taiwan, Ltd. (TWSE:1789), a specialty Active Pharmaceutical ingredient (API) company, and Lee’s Pharmaceutical Holdings Limited (950.HK) announced the execution of two collaboration agreements today.

ScinoPharm (TWSE:1789) an active pharmaceutical ingredient (API) specialty company, announced unaudited record results for its fiscal year 2013. The company posted a historically high NT$5.088 billion (US$167.6 million) in revenue,

Genovate Biotechnology Co. Ltd. (4130:TT) and ScinoPharm Taiwan Ltd. (1789:TT) announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B.